KIM-ANH DO to Biomarkers
This is a "connection" page, showing publications KIM-ANH DO has written about Biomarkers.
Connection Strength
0.166
-
Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design. Biometrics. 2016 09; 72(3):888-96.
Score: 0.058
-
Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease. J Alzheimers Dis. 2015; 44(3):917-25.
Score: 0.054
-
Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort. J Clin Oncol. 2023 09 20; 41(27):4360-4368.
Score: 0.024
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.018
-
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003 Dec; 123(5):850-7.
Score: 0.006
-
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6.
Score: 0.005